BACKGROUND: Rotavirus vaccine was recommended for routine use among US infants in 2006. To provide prevaccine data, we conducted strain surveillance for 9 consecutive seasons during 1996-2005. METHODS: Using reverse-transcriptase polymerase chain reaction genotyping and nucleotide sequencing, we determined P/G genotypes of >3100 rotavirus strains collected in up to 12 cities each year from different US regions. RESULTS: The most prevalent strain globally, P[8] G1, was the most prevalent each year in the United States (overall, 78.5% of strains; range, 60.0%-93.9%), and 9.2% of the samples were P[4] G2, 3.6% were P[8] G9, 1.7% were P[8] G3, and 0.8% were P[8] G4. Genotype P[6] G9, which emerged in 1995, was detected continuously for several seasons (from 1996-1997 to 2000-2001, 0.2%-5.4%) but was not identified in the subsequent 4 seasons. Single or a few detections of rare genotypes (eg, P[6] G12, P[9] G6, and P[9] G3) were observed during several rotavirus seasons at frequencies of 0.5%-1.7% and, overall, comprised 0.6% of all the samples from the entire surveillance period. Several globally common strains in addition to G1, especially G2 and G9, circulated at high prevalence (33%-62%) in some cities during certain years. CONCLUSIONS: Almost 85% of strains during 1996-2005 had either a G or P antigen that is present in both RotaTeq (Merck) and Rotarix (GlaxoSmithKline). Monitoring of strains after introduction of rotavirus vaccines is important.
BACKGROUND: Rotavirus vaccine was recommended for routine use among US infants in 2006. To provide prevaccine data, we conducted strain surveillance for 9 consecutive seasons during 1996-2005. METHODS: Using reverse-transcriptase polymerase chain reaction genotyping and nucleotide sequencing, we determined P/G genotypes of >3100 rotavirus strains collected in up to 12 cities each year from different US regions. RESULTS: The most prevalent strain globally, P[8] G1, was the most prevalent each year in the United States (overall, 78.5% of strains; range, 60.0%-93.9%), and 9.2% of the samples were P[4] G2, 3.6% were P[8] G9, 1.7% were P[8] G3, and 0.8% were P[8] G4. Genotype P[6] G9, which emerged in 1995, was detected continuously for several seasons (from 1996-1997 to 2000-2001, 0.2%-5.4%) but was not identified in the subsequent 4 seasons. Single or a few detections of rare genotypes (eg, P[6] G12, P[9] G6, and P[9] G3) were observed during several rotavirus seasons at frequencies of 0.5%-1.7% and, overall, comprised 0.6% of all the samples from the entire surveillance period. Several globally common strains in addition to G1, especially G2 and G9, circulated at high prevalence (33%-62%) in some cities during certain years. CONCLUSIONS: Almost 85% of strains during 1996-2005 had either a G or P antigen that is present in both RotaTeq (Merck) and Rotarix (GlaxoSmithKline). Monitoring of strains after introduction of rotavirus vaccines is important.
Authors: Virginia E Pitzer; Manish M Patel; Ben A Lopman; Cécile Viboud; Umesh D Parashar; Bryan T Grenfell Journal: Proc Natl Acad Sci U S A Date: 2011-11-14 Impact factor: 11.205
Authors: Jie Liu; Kate Lurain; Shihab U Sobuz; Sharmin Begum; Happiness Kumburu; Jean Gratz; Gibson Kibiki; Denise Toney; Rashi Gautam; Michael D Bowen; William A Petri; Rashidul Haque; Eric R Houpt Journal: J Virol Methods Date: 2014-12-17 Impact factor: 2.014
Authors: Slavica Mijatovic-Rustempasic; Ka Ian Tam; Tara K Kerin; Jamie M Lewis; Rashi Gautam; Osbourne Quaye; Jon R Gentsch; Michael D Bowen Journal: J Clin Microbiol Date: 2013-07-12 Impact factor: 5.948
Authors: Ka Ian Tam; Mathew D Esona; Alice Williams; Valantine N Ndze; Angeline Boula; Michael D Bowen Journal: J Virol Methods Date: 2015-05-30 Impact factor: 2.014
Authors: Margaret H Libonati; Allison F Dennis; Sasirekha Ramani; Sarah M McDonald; Asmik Akopov; Ewen F Kirkness; Gagandeep Kang; John T Patton Journal: J Virol Date: 2014-06-04 Impact factor: 5.103